It was a pleasure to be able to catch up with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) to discuss rosacea classification and how this can impact treatment choices.
Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021.
- Could you give us an overview of the incidence of rosacea? (0:05)
- Can you tell us about the classification of rosacea and how it has changed? (start 1:08)
- How do these features impact treatment choices and what should we be considering? (3:39)
Disclosures: Dr Esther van Zuuren has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed as a highlight of EADV Spring Symposium 2021 (Virtual).
Share this Video
Related Videos In Dermatological Conditions
Christian Vestergaard, EADV 2021: Biologics for Paediatric Skin Diseases
It was a pleasure to meet Dr Christian Vestergaard (Aarhus University Hospital, Aarhus, Denmark) to discuss the use of biologics in the treatment of paediatric skin diseases. His presentation entitled ‘The use of biological drugs for skin diseases in children’ was presented at the EADV 30th Congress, 29 Sep – 2 Oct 2021. Questions What […]
Rosalie Luiten, EADV 2021: The Role of Resident Memory T-cells in Vitiligo and Tumour Immunity
touchIMMUNOLOGY were delighted to discuss with Prof. Rosalie Luiten (University of Amsterdam, Amsterdam, The Netherlands) the role of resident memory T cells in autoimmune vitiligo and tumour immunity, and how they could be used as a therapeutic target. Her presentation entitled ‘Skin-resident T-cells as a potential new therapeutic target in vitiligo’ was given at the […]
Rosalie Luiten, EADV 2021: The Link between Vitiligo and Melanoma
It was a pleasure to discuss with Prof. Rosalie Luiten (University of Amsterdam, Amsterdam, The Netherlands) the immunological link between vitiligo and melanoma. Her presentation entitled ‘Skin-resident T-cells as a potential new therapeutic target in vitiligo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct. Questions How are vitiligo and melanoma linked? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!